Defining a longevity biotechnology company
N. Boekstein is director, corporate strategy at Cambrian Bio. N. Barzilai is the scientific director of the American Federation of Aging Research, on the executive board of the LBA and on the scientific advisory board of LVF and Human Edge. He is also a founder of CohBar Inc. and Life Biosciences and on the board of Sirtlab. A.B. is the CEO of HelpWear. J.B.-L. leads the longevity biotechnology company Retro Biosciences. K.F. is CEO of BioAge Labs. S.B.H.
is the co-founder and CEO of a biotechnology company, Oviva Therpaeutics, that is developing therapeutics to improve ovarian function and extend healthspan in females, and also holds shares in Cambrian Bio. She serves on the scientific board of Dior Beauty, their ‘Age Reversal’ board, dedicated to advising and educating on longevity science. D.A.S. is a consultant to, inventor of patents licensed to and, in some cases, board member of and investor in Fully Aligned Co.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
People - Nature BiotechnologyRecent moves of note in and around the biotech and pharma industries.
Leer más »
Connor Bedard: NHL draft a ‘defining moment’ for Chicago BlackhawksFrom funny guy to phenom, Connor Bedard — the presumptive No. 1 pick by the Chicago Blackhawks — has left lasting impressions with everyone he has encountered on his path to the NHL draft.
Leer más »
Austin Killips says trans athletes are ‘statistically underrepresented’ despite ‘nature of the discourse'Transgender female cyclist Austin Killips addressed the national debate surrounding trans athletes' participation in sports, adding that they are “statistically underrepresented.'
Leer más »
Opinion: What The OceanGate Incident Taught Us About Human NatureBillionaires, hubris and inappropriate jokes — maybe there is a lesson in the tragic loss.
Leer más »
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial - Nature MedicineIn a phase 2 randomized clinical trial in patients with severe hypertriglyceridemia, pegozafermin, a long-acting analog of human FGF21, was safe and met the primary endpoint of the trial for reducing serum triglyceride levels DLBHATTMD IcahnMountSinai
Leer más »